




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07H 13/06, A61K 7/48, 31/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/09862</b> <b>(43) International Publication Date:</b> 13 April 1995 (13.04.95)
<b>(21) International Application Number:</b> PCT/EP94/03187 <b>(22) International Filing Date:</b> 24 September 1994 (24.09.94) <b>(30) Priority Data:</b> 9320610.0                      6 October 1993 (06.10.93)                      GB <b>(71) Applicant (for all designated States except US):</b> CIBA-GEIGY AG [CH/CH]; Klybeckstrasse 141, CH-4002 Basle (CH). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MAIER, Thomas [DE/DE]; Am Untern Biefang 23, D-79418 Schliengen (DE). LUTHER, Helmut [DE/DE]; Tüllingerweg 3A, D-79639 Grenzach-Wyhlen (DE). <b>(74) Common Representative:</b> CIBA-GEIGY AG; Patentabteilung, Klybeckstrasse 141, CH-4002 Basle (CH).		<b>(81) Designated States:</b> AU, BR, CA, CZ, FI, HU, JP, KR, NZ, PL, SI, SK, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> WATER-SOLUBLE RETINOIDS <b>(57) Abstract</b> <p>The invention relates to novel water-soluble sugar retinoids (I) and to their preparation and the use thereof as medicaments and in the cosmetic sector, wherein X is a sugar radical attached at an oxygen atom, i.e. a mono-, di- or oligosaccharide, provided that X is not a glucose- or galactose sugar residue attached at the oxygen atom in the respective 1-positions of the glucose- or galactose sugar residues.</p> <div style="display: flex; align-items: center; justify-content: center;">  <span style="margin-left: 20px;">(I)</span> </div>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### Water-soluble retinoids


The present invention relates to water-soluble novel sugar retinoids, and to their preparation and the use thereof as medicaments and in the cosmetic sector.

Retinoic acid derivatives are commonly used in the field of dermatology. Thus keratinising epithelial tissue can be converted by retinoic acid or derivatives thereof into tissue of normally differentiated cells. The retinoids exert a protective action against chemically, photochemically or virally induced carcinogenesis and assume protective functions in cell division. Retinoic acid itself is water-insoluble and is therefore usually converted into a water-soluble form for ease of handling.

Aromatic retinoids having a saccharide or aminosaccharide radical, and which are suitable dermatological agents for use in pharmaceuticals and cosmetics, are disclosed in US-A-4 565 863. For toxicological reasons, such aromatic retinoids are sought to be avoided.

Certain new water-soluble aliphatic derivatives of retinoic acid have now been found which are excellent dermatological agents for use in pharmaceuticals and cosmetics.

Accordingly, the present invention provides retinoic acid esters of formula (I)



wherein X is a sugar residue attached at an oxygen atom, i.e. a mono-, di- or oligosaccharide, provided that X is not a glucose- or galactose sugar residue attached at the oxygen atom in the respective 1-positions of the glucose- or galactose sugar residues.

The double bonds in the retinoic acid radical may be in cis- or trans-configuration, the all-trans-form being preferred.

Oligosaccharides containing more than two sugar units may suitably be in particular compounds such as streptomycin, neuraminic acid, fucose,  $\alpha,\beta,\gamma$ -cyclodextrin, raffinose or

- 2 -

short-chain degradation products of amylose or cellulose.

The sugar radical is preferably a mono- or disaccharide which is derived from ribose, arabinose, xylose, glucose, mannose, galactose, lactose, saccharose, trehalose, cellobiose, maltose, fructose or derivatives thereof.



Suitable derivatives of these sugars include:

desoxy sugars; the lactones of the corresponding sugar acids such as gluconic acid  $\gamma$ -lactone which in turn may be esterified by  $C_1$ - $C_4$ alkyl; uronic acids; amino sugars having an unsubstituted amino group, typically glucosamine, fructosamine, galactosamine, or having a  $C_1$ - $C_6$ alkyl- or  $C_1$ - $C_6$ acetyl-substituted amino group, e.g. aminoethyl-glucosides, aminoethyl-2-deoxy-2-aminoglucoside, N-acetylaminoglucoside; sugars in which the OH groups are substituted by one or more than one  $C_1$ - $C_4$ alkoxy group, e.g. methyl or ethyl glucose, substitution by  $C_1$ - $C_4$ alkylene bridges also being possible; keto-sugar acids such as ascorbic acid; sugars in which the OH groups are mono- or polyacetylated, typically glucose acetate or 2,3,4-tri-O-acetylglucose; or sugars carrying several different substituents, e.g. neuraminic acid.


Particularly preferred sugars are glucose, galactose, mannose or derivatives thereof.

The aforementioned sugar radicals may also be in the form of racemates or any mixtures of the (L)- and (D)-configuration as well as in the form of the pure (L)- or (D)-isomers. The natural (D)-configuration is preferred.

Compounds of formula Ia, Ib or Ic are of particular importance:



- 3 -



wherein

$R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are OH,  $C_1$ - $C_4$ alkoxy,  $C_1$ - $C_3$ -COO-, or two of these radicals taken together are a O- $C_1$ - $C_4$ -O-alkylene bridge;

as well as the isomers of the compounds (Ia) and (Ib) in which the saccharide moiety is in the furanose form.

The novel compounds of formula (I) are prepared by

- a) converting retinoic acid into a reactive derivative, and
- b) adding a mono-, di- or oligosaccharide.

To enhance its reactivity, the retinoic acid can be converted into a reactive derivative such as an imidazolide, a mixed anhydride or an acid chloride. The acid chloride is preferred. This conversion is preferably carried out with chloroamine or dimethylchloroformamidinium chloride, using any solvent which is inert to the chlorinating reagent and which at least partially dissolves the retinoic acid, conveniently selected from among ethers, amides, aromatic hydrochlorides, esters, halogenated hydrocarbons, nitriles and sulfoxides. Typical examples of such solvents are methylene chloride, dimethyl formamide, toluene, ethyl acetate, acetonitrile, dimethyl sulfoxide and hexane.

To obtain the retinoic acid esters of formula I, Ia, Ib or Ic, the sugar can be used in already derivatised form or it is derivatised after the linkage to the retinoic acid or after the sulfation. It is preferred to use sugars in which the OH groups that are not to be esterified are provided with protective groups so as to achieve a selective linkage of the sugar to the acid chloride. The protective groups used for this purpose are normally diol protective groups such as isopropylidene, benzylidene or ethylene protective groups, and they are prepared in known manner. After the linkage of the sugar to the retinoic acid, these groups can be removed again in known manner.

The reaction of the sugar with the retinoic acid derivative preferably takes place under the same conditions as are used for the derivatisation of the retinoic acid, and a base such as

- 4 -

pyridine can be added to promote the reaction.

It has been found that the compounds of formula (I) can be used for the cosmetic and pharmacological treatment of the eyes or skin, for example for tautening and rejuvenating the skin, for the treatment of acne, psoriasis, neoplasms, dermatoses, as well as for preventive treatment to provide protection from ultraviolet radiation.

For pharmaceutical application, the compounds of formula (I) are formulated with conventional carriers.

Topical application is preferred. Such application comprises treating the skin with an effective amount of the compound of formula (I).

A pharmaceutical or cosmetic composition containing a compound of formula (I) may be administered or applied in the form of tablets, granules, capsules, dragées, ointments, creams, tinctures, lotions, solutions, suspensions, hydrogels, liposomes or foam sprays.

Suitable carriers include mixtures of different emulsifiers, dispersants, stabilisers, perfume oils, antioxidants, thickeners, diluents, humectants, fillers, salts for changing the osmotic pressure, and buffers. Typical examples of such carriers are gelatin, lactose, starch, fatty acid salts, talcum, gum arabic, polyalkylene glycols and other non-toxic excipients.


The concentration of active ingredient may be from 0.01 to 5 % by weight, depending on the dosage form.

The following examples illustrate the invention.

#### Example 1

- Linkage of retinoic acid to 1,2:3,4-diisopropylidene- $\alpha$ -D-galactopyranose

- 5 -



21 g of all-trans-retinoic acid (1) are suspended, under nitrogen, in 250 ml of methylene chloride. With stirring, 9.9 ml of chloroenamine are slowly added to the suspension. The clear orange solution is stirred for a further 30 minutes at  $0^\circ\text{C}$ . To this solution is added a solution of 1,2:3,4-diisopropylidene- $\alpha$ -D-galactopyranose in 70 ml of methylene chloride and 11 ml of pyridine. After this addition, the ice bath is removed and stirring is continued for another hour. For working up, the solution is concentrated to dryness and the residue is taken up in petroleum/ethyl acetate (15/1) and purified over a silica gel column with petroleum ether/ethyl acetate (15/1). The yield of all-trans-1,2:3,4-diisopropylidene-6-retinoyl- $\alpha$ -D-galactopyranose (3) is from 73 to 87%.


#### - Removal of the protective groups

25 g of 1,2:3,4-diisopropylidene-6-retinoyl- $\alpha$ -D-galactopyranose (3) are dissolved in 200 ml of tetrahydrofuran. Then 20 ml of 2N sulfuric acid are added and the reaction mixture is refluxed for 12 hours. For working up, the reaction solution is neutralised with

- 6 -


sodium hydrogencarbonate, and the product is extracted with methylene chloride, concentrated to dryness on a rotary evaporator and taken up in methylene chloride/methanol (7/1) and purified over a silica gel column with methylene chloride/methanol (7/1).

The yield of product of formula (4) is 79%.



The protected  $\alpha$ -D-galactopyranose of Example 1 is replaced with the following sugars (unprotected or in suitably protected form): ribose, arabinose, xylose, lactose, saccharose, trehalose, cellobiose, maltose, fructose, neuraminic acid, fucose,  $\alpha,\beta,\gamma$ -cyclodextrin or raffinose, to give water-soluble derivatives of retinoic acid which can be used for the cosmetic and pharmacological treatment of the eyes or skin.


**Example 2:** In accordance with the general procedure described in Example 1, reaction of all-trans-retinoic acid (1) and 1,2:5,6-di-O-isopropylidene-D-glucose, followed by subsequent removal of the protective groups, gives a compound of formula (5)




**Example 3:** In accordance with the general procedure described in Example 1, reaction of all-trans-retinoic acid (1) and 1,2:4,5-di-O-isopropylidene-D-fructose, followed by subsequent removal of the protective groups, gives a compound of formula (6)



- 7 -



**Example 4:** In accordance with the general procedure described in Example 1, reaction of all-trans-retinoic acid (1) and 2,3:5,6-di-O-isopropylidene-α-D-mannofuranose, followed by subsequent removal of the protective groups, gives a compound of formula (7)



**Example 5:**

A cream of the following composition is prepared

- 0.05 % of the compound of formula (5) of Example 2
- 2.00 % of Amphisol<sup>®</sup>
- 2.50 % of stearic acid
- 3.50 % of glyceryl myristate
- 5.00 % of isopropyl myristate
- 3.00 % of 1,2-propylene glycol
- 0.10 % of triethanolamine
- 0.55 % of sodium hyalurate
- 0.02 % of propyl parabene
- 0.18 % of methyl parabene
- perfume oils as required, and demineralised water to make up
- 100 %

The triethanolamine, sodium hyalurate, parabene, propylene glycol and water are heated to 75°C and a mixture of the fat-soluble components, also heated to 75°C, is added, and the entire mixture is homogenised. After cooling, with stirring, to 40°C, the mono-saccharide retinoic acid ester (5) and optional perfume oils are added.

Example 6: The procedure of Example 5 is repeated, but using a compound of formula (4) of Example 1 as monosaccharide.

Example 7: The procedure of Example 5 is repeated, but using a compound of formula (6) of Example 3 as monosaccharide.

Example 8: The procedure of Example 5 is repeated, but using a compound of formula (7) of Example 4 as monosaccharide.

Example 9:

A transparent hydrogel of the following composition is prepared:

0.1 %	of the compound of formula (5) Example 2
20.0 %	of 1,2-propylene glycol
20.0 %	of isopropanol
2.0 %	of acrylic acid polymer
3.0 %	of triethanolamine
perfume oils as required, and demineralised water to make up	
100 %	

The acrylic acid polymer and water are dispersed and the dispersion is neutralised with triethanolamine. The monosaccharide retinoic acid ester (5) is dissolved in a mixture of isopropanol and propylene glycol and the solution is mixed with other components to a gel.

Example 10: The procedure of Example 9 is repeated, but using a compound of formula (4) of Example 1 as monosaccharide.

Example 11: The procedure of Example 9 is repeated, but using a compound of formula (6) of Example 3 as monosaccharide.

Example 12: The procedure of Example 9 is repeated, but using a compound of formula (7) of Example 4 as monosaccharide.

Example 13:

A foam spray of the following composition is prepared:

- 9 -

0.03 % of the compound of formula (5) of Example 2  
5.00 % of 1,2-propylene glycol  
1.70 % of cetyl alcohol  
1.00 % of paraffin oil, viscous  
2.00 % of isopropyl myristate  
2.40 % of Cetomacrogol 1000®  
1.50 % of sorbitan monostearate  
0.18 % methyl parabene  
0.10 % propyl parabene  
0.10 % of Chemoderm 314®  
perfume oils as required, and demineralised water to make up  
100 %

Cetyl alcohol, paraffin oil, isopropyl myristate, Cetomacrogol 1000® and sorbitan stearate are fused and the methyl- and propyl parabene, dissolved in propylene glycol, and hot water are added at 75°C and the mixture is homogenised. After cooling to 40°C, the monosaccharide retinoic acid ester (5), Chemoderm 314® and optional perfume oils are added. 20 ml of the mixture are filled into an aluminium lacquer-coated container which is closed with a valve and filled with propellant gas under pressure.

Example 14: The procedure of Example 13 is repeated, but using a compound of formula (4) of Example 1 as monosaccharide.

Example 15: The procedure of Example 13 is repeated, but using a compound of formula (6) of Example 3 as monosaccharide.

Example 16: The procedure of Example 13 is repeated, but using a compound of formula (7) of Example 4 as monosaccharide.

Example 17: In accordance with the test method of L.H. & A.M.Kligman [The effect on rhino mouse skin of agents which influence keratinisation and exfoliation, J.Invest.Dermatol.,73, 354-358 (1979)], rhino mice are treated for 3 weeks, twice a day, each time with a) a 0,05% solution of the compound of formula (5), namely glucose retinate, or with b) a 0.025% solution of retinic acid, the solvent in each case being ethanol:polyethylene glycol (90:10, v:v).


- 10 -

The two test compounds provide a comparable normalisation of the skin structure (reduction of the utriculi). Retinic acid, however, causes, as a side effect, a significant reddening of the skin, which undesirable effect is not observed with the compound of formula (5).

Example 18: In order to detect any possible teratogenic effect, the compound of formula (5) is tested, using retinic acid as a comparison, in a rat embryo culture using the method of L.Cicurel & B.P.Schmid [Postimplantation embryo culture for the assessment of the teratogenic potential and potency of compounds, *Experientia* **44**, 833-40 (1988)]. Whereas retinic acid induces malformations, even at a concentration of 0.3 µg/ml, no malformations occur at up to 10 µg/ml with the compound of formula (5).

What is claimed is:

1. A retinoic acid ester of formula (I)






wherein X is a sugar radical attached at an oxygen atom, i.e. a mono-, di- or oligosaccharide, provided that X is not a glucose- or galactose sugar residue attached at the oxygen atom in the respective 1-positions of the glucose- or galactose sugar residues.

2. A compound according to claim 1, wherein the retinoic acid radical is in the all-trans form.
3. A compound according to claim 1, wherein  
X is a mono- or disaccharide which is derived from ribose, arabinose, xylose, glucose, mannose, galactose, lactose, saccharose, trehalose, cellobiose, maltose, fructose or derivatives thereof.
4. A compound according to claim 3, wherein X is glucose, galactose, mannose or a derivative thereof.
5. A compound according to either claim 3 or claim 4, wherein M is hydrogen or an alkali metal ion.
6. A compound according to either claim 3 or claim 4, wherein M is hydrogen, sodium or potassium.
7. A compound according to any one of claims 1 to 6, wherein the OH groups are each independently of one another unsubstituted or substituted by C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>3</sub>-COO-, or two OH groups taken together may be substituted by a O-C<sub>1</sub>-C<sub>4</sub>-O-alkylene bridge.

- 12 -

8. A compound of formula Ia, Ib or Ic



wherein

$R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are OH,  $C_1$ - $C_4$ alkoxy,  $C_1$ - $C_3$ - $COO^-$ , or two of these radicals taken together are a  $O-C_1-C_4-O$ -alkylene bridge;  
or an isomer of the compounds (Ia) and (Ib) in which the saccharide moiety is in the furanose form.

9. A compound according to claim 8, wherein each of the substituents  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  is OH.

10. A process for the preparation of a compound of formula (I), which comprises

- a) converting retinoic acid into a reactive derivative and
- b) adding a mono-, di- or oligosaccharide.

11. A process for the preparation of a compound of formula (I) according to claim 9, which comprises converting retinoic acid into an acid chloride.

12. A process for the preparation of a compound of formula (I) according to claim 11, which comprises converting retinoic acid into an acid chloride with chloroamine or

- 13 -

dimethylchloroformamidinium chloride.

13. A process for the preparation of a compound of formula (I) according to claim 12, which comprises carrying out the reaction with chloroamine.

14. A process for the preparation of a compound of formula (I) according to any one of claims 10 to 13, which comprises using a sugar which carries protective groups.

15. A process for the preparation of a compound of formula (I) according to claim 14, which comprises using diol protective groups as protective groups for the saccharide.

16. A process for the preparation of a compound of formula (I) according to either claim 14 or claim 15, which comprises removing the protective groups for the saccharide again after the linkage of the sugar to the retinoid.

17. A pharmaceutical or cosmetic composition comprising a compound as claimed in any one of claims 1 to 9, and a carrier.

18. Use of a compound as claimed in any one of claims 1 to 9 for the preparation of a composition for the treatment of acne, psoriasis, neoplasms, dermatoses and for preventive treatment to provide protection from ultraviolet radiation.

19. Use according to claim 18 which consists of topical application.

## INTERNATIONAL SEARCH REPORT

Inter:    nal Application No  
PCT/EP 94/03187

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6    C07H13/06    A61K7/48    A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6    C07H    A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	INTERNAT. J. VIT. NUTR. RES., vol.61, 1991 pages 258 - 263 A.B. BARUA ET AL. 'All-trans Retinoyl Beta-Glucose: Chemical Synthesis, Growth-Promoting Activity and Metabolism in the Rat' see the whole document ---	1-4, 17, 18
Y	WO,A,90 14093 (IOWA STATE UNIVERSITY RESEARCH FOUNDATION) 29 November 1990 see the whole document ---	1-4, 17, 18
X	EP,A,0 356 154 (SAWAI PHARMACEUTICAL) 28 February 1990 see page 40, column 1C-15; claims 1-3; examples iv-6, 1c-15 --- -/--	1-3, 7

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

25 November 1994

Date of mailing of the international search report

21.12.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Brennan, J



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 94/03187

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 388 308 (L'OREAL) 19 September 1990 see claims 1,2,4,8,10 ---	1,2,7, 17,18
X	EP,A,0 315 540 (L'OREAL) 10 May 1989 see claims 1,3,7 ---	1,2,7, 17,18
X	FR,A,2 598 420 (L'OREAL) 13 November 1987 see claims 1,3,10 ---	1,2,7, 17,18
P,X	WO,A,93 21195 (CIBA-GEIGY) 28 October 1993 see page 3 - page 8	1-4,7-10
P,Y	see the whole document -----	1-4,17, 18

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/ 03187

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 5,6  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Claims 5 and 6 relate to a feature M, not otherwise described or defined in the application.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

information on patent family members

Interr. al Application No

PCT/EP 94/03187

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9014093	29-11-90	AU-B- 618198 AU-A- 5740690 CA-A- 2033183 EP-A- 0428668 JP-T- 4500684 US-A- 5075340	12-12-91 18-12-90 23-11-90 29-05-91 06-02-92 24-12-91
EP-A-0356154	28-02-90	US-A- 5049664 JP-A- 3047193	17-09-91 28-02-91
EP-A-0388308	19-09-90	FR-A- 2644460 CA-A- 2012219 DE-D- 69008761 DE-T- 69008761 ES-T- 2052200 JP-A- 2268192 US-A- 5091522	21-09-90 16-09-90 16-06-94 25-08-94 01-07-94 01-11-90 25-02-92
EP-A-0315540	10-05-89	LU-A- 87041 DE-A- 3870582 JP-A- 1193293 US-A- 5045533	14-06-89 04-06-92 03-08-89 03-09-91
FR-A-2598420	13-11-87	BE-A- 1004152 CA-A- 1300131 CH-A- 674847 DE-A- 3714937 DK-B- 169345 GB-A,B 2191483 JP-A- 62289593 NL-A- 8701054 SE-B- 470379 SE-A- 8701845 US-A- 5045533	06-10-92 05-05-92 31-07-90 12-11-87 10-10-94 16-12-87 16-12-87 01-12-87 07-02-94 07-11-87 03-09-91
WO-A-9321195	28-10-93	CH-A- 684092 AU-B- 3952993 SI-A- 9300207	15-07-94 18-11-93 31-12-93